Kite Pharma (KITE) trading halted with news pending
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Kite Pharma (KITE) Shares Pop Higher on Trading Resumption
September 26, 2016 4:32 PM EDTKite Pharma (NASDAQ: KITE) shares rise upon resumption. The stock was up as much as 16 percent this afternoon.
... MoreKite Pharma (KITE) to resume trading at 4:30PM ET
September 26, 2016 4:06 PM EDTKite Pharma (NASDAQ: KITE) is expected to resume trading at 4:30PM ET
... MoreKite Pharma (KITE) Announces Positive Topline Data from KTE-C19 ZUMA-1 Study in Aggressive NHL
September 26, 2016 4:02 PM EDTKite Pharma, Inc., (Nasdaq: KITE) announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 met the primary endpoint of objective response rate (ORR), p... More
